Evidence map›Paper›PMID 39311602›Full record

ArticleJournal of visualized experiments : JoVE2024

Development and Application of Rapamycin-regulated Tyrosine Phosphatases.

Barbara N Szynal, Hanna Bradford-Olson, Andrei V Karginov

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Barbara N SzynalDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago.
Hanna Bradford-OlsonDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago.
Andrei V KarginovDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago; karginov@uic.edu.

Funding

Synthetic Biology and Optogenetics CoreP01HL151327 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MEHTA, DOLLY · 2021 to 2025
$11.8M
Regulation of endothelial cell invasion, migration and cell junction plasticityR35GM145318 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ANDREI V KARGINOV · 2022 to 2026
$2.2M
Optogenetic Control of Tumor Initiation and Tumor Progression in vivoR33CA258012 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARGINOV, ANDREI V, REHMAN, JALEES · 2022 to 2024
$1.2M
NCI NIH HHS R33 CA258012NHLBI NIH HHS P01 HL151327NIGMS NIH HHS R35 GM145318
6 · The paper itself

Abstract

Tyrosine phosphatases are an important family of enzymes that regulate critical physiological functions. They are often dysregulated in human diseases, making them key targets of biological studies. Tools that enable the regulation of phosphatase activity are instrumental in the dissection of their function. Traditional approaches, such as overexpression of constitutively active or dominant negative mutants, or downregulation using siRNA, lack temporal control. Phosphatase inhibitors often have poor specificity, and they only allow researchers to determine what processes are affected by the inhibition of the phosphatase. We developed a chemogenetic approach, the Rapamycin-regulated (RapR) system, which allows for allosteric regulation of a phosphatase catalytic domain that enables tight temporal control of phosphatase activation. The RapR system consists of an iFKBP domain inserted into an allosteric site in the phosphatase. The intrinsic structural dynamics of the RapR domain disrupt the catalytic domain, leading to the inactivation of the enzyme. The addition of rapamycin mediates the formation of a complex between iFKBP and a co-expressed FRB protein, which stabilizes iFKBP and restores activity to the phosphatase's catalytic domain. This system provides high specificity and tight temporal control of phosphatase activation in living cells. The unique capabilities of this system enable the identification of transient events and interrogation of individual signaling pathways downstream of a phosphatase. This protocol describes guidelines for the development of a RapR-phosphatase, its biochemical characterization, and the analysis of its effects on downstream signaling and regulation of cell morphodynamics. It also provides a detailed description of a protein engineering strategy, in vitro assays analyzing phosphatase activity, and live cell imaging experiments identifying changes in cell morphology.

Indexed as

Protein Tyrosine PhosphatasesSirolimusAllosteric RegulationCatalytic DomainHumansProtein Tyrosine PhosphatasesSirolimus

Identifiers

PMID39311602
PMCPMC12147672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.